Updates on current research

Greer, a leading developer and supplier of allergy immunotherapy products and services, has completed enrollment for its polar Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy (SLIT) as a treatment for adults with allergic rhinoconjunctivitis caused by shortsighted ragweed pollen. Between March and June, 556 patients were screened for the randomized, double-blind, placebo-controlled trial, of which 430 were enrolled. The participants will be observed at 31 clinical sites across the area. The trial will last approximately seven months, end in mid-October to coincide with the completion of the short ragweed pollen season. This work is significant because it is the first large Phase III trial conducted in the United States for the sublingual-oral administration of fluid allergenic extracts.